|
Immunitybio inc (NASDAQ: IBRX) |
|
Immunitybio inc
IBRX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Immunitybio Inc growth rates, revenue grew
by 41192.5 % in the first quarter of 2025 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 11.44 %
Immunitybio Inc net loss decreased from $-134 millions, to $-130 millions in first quarter of 2025,
• More on IBRX's Growth
|
|
Immunitybio Inc realized a net loss in trailing twelve months.
Immunitybio Inc realized cash reduction of $ -0.08 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 68.04.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.83.
• More on IBRX's Valuation
|
|
|
|
|
Immunitybio Inc realized net loss in trailing twelve months.
Immunitybio Inc realized cash outflow of $ -0.08per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 68.04.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.83.
• More on IBRX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com